Therapeutic advances in narcolepsy

Sleep Medicine

Volumn 8, Issue 4, 2007, Pages 427-440

  Thorpy, Michael ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Narcolepsy

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CAFFEINE; CARBEX; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; ETHINYLESTRADIOL; FEMOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OXYBATE SODIUM; PAROXETINE; PEMOLINE; PHENELZINE; PLACEBO; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

ANOREXIA; ARTICLE; BEHAVIOR THERAPY; CATAPLEXY; CLINICAL TRIAL; COMORBIDITY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG WITHDRAWAL; EDEMA; EJACULATION DISORDER; EMOTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; IMPOTENCE; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MUSCLE TWITCH; NARCOLEPSY; NAUSEA; NERVOUSNESS; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESSNESS; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOMNOLENCE; SWEATING; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; WAKEFULNESS; WEIGHT GAIN; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; IMMUNOTHERAPY; METHYLPHENIDATE; NARCOLEPSY; QUALITY OF LIFE; SELEGILINE; SEROTONIN UPTAKE INHIBITORS; SODIUM OXYBATE;

EID: 34248179572     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.03.004     Document Type: Article

References (128)

1. Hublin C. Narcolepsy. Current drug treatment options. CNS Drugs 5 (1996) 426-436
2. U.S. Modafinil in Narcolepsy Multicenter Study Group: randomized trial of modafinil as a treatment for excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-75.
3. Overeem S., Mignot E., van Dijk J.G., et al. Narcolepsy: clinical features, new pathological insights, and future perspectives. J Clin Neurophysiol 18 (2001) 78-105
4. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2 (2001) 5-17
5. Krahn L.E., Lymp J.F., Moore W.R., Slocumb N., and Silber M.H. Characterizing the emotions that trigger cataplexy. J Neuropsychiatry Clin Neurosci 17 (2005) 45-50
6. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 Suppl. 1 (1998) S16-S22
7. Ohayan M.M., Priest R.G., Zully J., et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 58 (2002) 1826-1833
8. Morrish E., King M.A., Smith I.E., and Shneerson J.M. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 5 (2004) 37-41
9. Passouant P., and Billiard M. The evolution of narcolepsy with age. In: Guilleminault C., Dement W.C., and Passouant P. (Eds). Narcolepsy (1976), Spectrum, New York 179-196
10. Broughton W.A., and Broughton R.J. Psychosocial impact of narcolepsy. Sleep 17 8 Suppl. (1994) S45-S49
11. Vignatelli L., D'Alessandro R., Mosconi P., Ferini-Strambi L., Guidolin L., De Vencentiis A., et al. Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey. Sleep Medicine 5 (2004) 467-475
12. Nishino S., Reid M.S., Dement W.C., et al. Neuropharmacology and neurochemistry of canine narcolepsy. Sleep 17 8 Suppl. (1994) S84-S92
13. Aldrich M.S., Prokopowicz G., Ockert K., et al. Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 17 7 (1994) 598-608
14. Aldrich M.S., Hollingsworth Z., and Penney J.B. Autoradiographic studies of post-mortem human narcoleptic brain. Neurophysiol Clin 23 1 (1993) 35-45
15. Aldrich M.S., Hollingsworth Z., and Penney J.B. Dopamine-receptor autoradiography of human narcoleptic brain. Neurology 42 2 (1992) 410-415
16. Lin L., Faraco J., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene [see comments]. Cell 98 3 (1999) 365-376
17. Chemelli R.M., Willie J.T., Sinton C.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation [see comments]. Cell 98 4 (1999) 437-451
18. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 9197 (2000) 39-40
19. Crocker A., Espana R.A., Papadopoulou M., Saper C.B., Faraco J., Sakurai T., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65 8 (2005) 1184-1188
20. Mitler M.M., Aldrich M.S., Koob G.F., et al. Narcolepsy and its treatment with stimulants. Sleep 17 4 (1994) 352-371
21. Bassetti C., and Aldrich M.S. Narcolepsy. Neurol Clin 14 3 (1996) 545-571
22. Aldrich M.S. Narcolepsy. N Engl J Med 323 6 (1990) 389-394
23. Auger R.R., Goodman S.H., Silber M.H., Krahn L.E., Pankratz V.S., and Slocumb M.L. Risks of high dose stimulants in the treatment of disorders of excessive somnolence. A case control study. Sleep 28 (2005) 667-672
24. Rogers A.E., Aldrich M.S., Berrios A.M., et al. Compliance with stimulant medications in patients with narcolepsy. Sleep 20 1 (1997) 28-33
25. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 95 Suppl. (1983) 57-80
26. Mayer G., Ewert Meier K., and Hephata K. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18 4 (1995) 306-319
27. Reinish L.W., MacFarlane J.G., Sandor P., et al. REM changes in narcolepsy with selegiline. Sleep 18 5 (1995) 362-367
28. Hublin C., Partinen M., Heinonen E.H., et al. Selegiline in the treatment of narcolepsy. Neurology 44 11 (1994) 2095-2101
29. Schneider L.S., Tariot P.N., and Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 56 6 Pt 2 (1994) 750-756
30. Ferraro L., Antonelli T., O'Connor W.T., et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 42 12 (1997) 1181-1183
31. Gold L.H., and Balster R.L. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 126 4 (1996) 286-292
32. Tanganelli S., Fuxe K., Ferraro L., et al. Inhibitory effects of the psychoactive drug modafinil on gamma- aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 345 4 (1992) 461-465
33. Ferraro L., Tanganelli S., O'Connor W.T., et al. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 220 1 (1996) 5-8
34. Ferraro L., Antonelli T., Tanganelli S., et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 20 4 (1999) 346-356
35. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., and Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21 5 (2001) 1787-1794
36. Wisor J.P., and Eriksson K.S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 132 4 (2005) 1027-1034
37. Mignot E., Nishino S., Guilleminault C., et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17 5 (1994) 436-437
38. Saletu B., Frey R., Krupka M., et al. Differential effects of a new central adrenergic agonist-modafinil- and d-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res 9 3 (1989) 183-195
39. Broughton R.J., Fleming J.A., George C.F., et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49 2 (1997) 444-451
40. Billiard M., Besset A., Montplaisir J., et al. Modafinil: a double-blind multicentric study. Sleep 17 8 Suppl. (1994) S107-S112
41. Boivin D.B., Montplaisir J., Petit D., et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 16 1 (1993) 46-53
42. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998;43(1):88-97.
43. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000;54(5):1166-75.
44. Hartse K.M., Roth T., and Zorick F.J. Daytime sleepiness and daytime wakefulness: the effect of instruction. Sleep 5 (1982) S107-S118
45. Thorpy M.J. The clinical use of the Multiple Sleep Latency Test. Sleep 15 (1992) 268-276
46. Patel S.R., White D.P., Malhotra A., Stanchina M.L., and Ayas N.T. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Arch Intern Med 163 (2003) 565-571
47. Mitler M.M., Harsh J., Hirshkowitz M., et al. Long-term efficacy and safety of modafinil (Provigil) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 1 3 (2000) 231-243
48. Littner M., Johnson S.F., McCall W.V., Anderson W.M., Davila D., Hartse K., et al., for the American Academy of Sleep Medicine Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 20 00. Sleep 24 (2001) 451-466
49. Besset A., Chetrit M., Carlander B., and Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 26 (1996) 60-66
50. Billiard M., Besset A., Montplaisir J., Laffont F., Goldenberg F., Weill J.S., et al. Modafinil: a double-blind multicentric study. Sleep 17 8 Suppl. (1994) S107-S112 37
51. U.S. Xyrem® International Study Group: a double blind placebo controlled study demonstates sodium oxybate is effective for the treatment of excessive sleepiness in narcolepsy. J Clin Sleep Med 2005; 1(4):391-397. 704-6.
52. Smith D.E., Calhoun S.R., Galloway G.P., Romanoff S.J., and Wolfe N.E. Postmarketing surveillance of modafinil abuse and misuse (abstract). Sleep 27 Suppl. (2004) A57
53. Rush C.R., Kelly T.H., Hays L.R., Baker R.W., and Wooten A.F. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 13 (2002) 105-115
54. Jasinski D.R., and Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 23 (2000) 149-156
55. Schwartz J.R.L., Feldman N.T., Bogan R.K., Nelson M.T., and Hughes R.J. Dosing regimen effects of narcolepsy for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 26 (2003) 252-257
56. Schwartz J.R.L., Feldman N.T., and Bogan R.K. Dose response and dose regimen effects of modafinil in sustaining daytime wakefulness in narcolepsy patients with residual excessive sleepiness. J Neurol Clin Neurosci J Neuropsychiatry Clin Neurosci 17 3 (2005) 405-412
57. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., and Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72 (2002) 179
58. Dinges D.F., Arora S., Darwish M., and Niebler G.E. Curr Med Res Opin 22 1 (2006) 159-167
59. Takahara J., Yunoki S., Yakushiji W., Yamauchi J., and Yamanae Y. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 44 (1977) 1014-1017
60. Teter C.J., and Guthrie S.K. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 21 (2001) 1486-1513
61. Food and drug administration: gamma hydroxybutyric acid. Press release. Rockville, MD: November 8, 1990.
62. Centers for disease control: multistate outbreak of poisonings associated with illicit use of gamma hydroxybutyrate. J Am Med Assoc 1991;256:447-8.
63. Drug enforcement administration: schedules of controlled substances: addition of gamma hydroxybutyric acid to schedule I. Fed Reg 2000;65:13235-8.
64. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol 3 (1964) 433-452
65. Mamelak M., Escriu J.M., and Stokan O. The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry 12 (1977) 273-288
66. Broughton R., and Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci 7 (1980) 23-31
67. Scharf M., Brown D., Woods M., Brown L., and Hirschowitz J. The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. J Clin Psych 46 (1985) 222-225
68. Scrima L., Hartman P.G., Johnson Jr. F.H., and Hiller F.C. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 26 (1989) 331-343
69. Scrima L., Hartman P.G., Johnson Jr. F.H., Thomas E.E., and Hiller F.C. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 13 (1990) 479-490
70. Lammers G.J., Arends J., Declerk A.C., Ferrari M.D., Schouwink G., and Troost J. Gamma-hydroxybutyrate and narcolepsy: a double- blind placebo-controlled study. Sleep 16 (1993) 216-220
71. Tunnicliffe G. Significance of γ-hydroxybutyric acid in the brain. Gen Pharmacol 23 (1992) 1027-1034
72. Maitre M. The γ-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol 51 (1997) 337-361
73. B receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 287 (1998) 262-265
74. Scharf M.B., Lai A.A., Branigan B., Stover R., and Berkowitz D.B. Pharmacokinetics of gamma-hydroxybutyrate (GHB) in narcoleptic patients. Sleep 21 (1998) 507-514
75. ® (sodium oxybate). A study of dose proportionality in healthy human subjects. J Clin Pharmacol 40 (2000) 1053
76. Borgen L.A., Okerholm R., Morrison D., and Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 43 (2003) 59-65
77. Borgen L.A., Okerholm R.A., and Scharf M.B. The pharmacokinetics of sodium oxybate following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 44 (2004) 253-257
78. Nelson T., Kaufaman E., Kline J., and Sokoloff L. The extraneural distribution of γ-hydroxybutyrate. J Neurochem 37 (1981) 1345-1348
79. Kaufman E.E., and Nelson T. An overview of gamma-hydroxybutyrate catabolism: the role of the cytosolic NADP(+)-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway. Neurochem Res 16 (1991) 965-974
80. U.S. Xyrem® Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25(1):42-9.
81. U.S. Xyrem® Multicenter Study Group. A 12-month, open-label, multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26:31-5.
82. Akimoto H., Honda Y., and Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv System 21 (1960) 704-706
83. Guilleminault C., Raynal D., Takahashi S., et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 54 (1976) 71-87
84. Hishikawa Y., Ida H., Nakai K., et al. Treatment of narcolepsy with imipramine (Tofranil) and desmethylimipramine (Pertofran). J Neurol Sci 3 (1966) 453-461
85. Guilleminault C., Wilson R.A., and Dement W.C. A study on cataplexy. Arch Neurol 31 (1974) 255-261
86. Houghton W.C., Scammell T.E., and Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev 8 (2004) 355-366
87. Shapiro W.R. Treatment of cataplexy with clomipramine. Arch Neurol 32 (1975) 653-656
88. Chen S.Y., Clift S.J., Dahlitz M.J., et al. Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine. J Sleep Res 4 (1995) 113-118
89. Martinez-Rodriguez J., Iranzo A., Santamaria J., et al. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 17 (2002) 113-116
90. Frey J., and Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 44 (1994) 707-709
91. Langdon N., Shindler J., Parkes J.D., et al. Fluoxetine in the treatment of cataplexy. Sleep 9 (1986) 371-373
92. Wyatt R.J., Fram D.H., Buchbinder R., et al. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med 285 (1971) 987-991
93. Parkes J.D., and Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurol Scand 60 (1979) 250-254
94. Iijima S., Sugita Y., Teshima Y., and Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 9 1 Pt 2 (1986) 265-268
95. Smith M., Parkes J.D., and Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 5 Suppl. 1 (1996) 217
96. Schrader H., Kayed K., Bendixen Markset A.C., et al. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 74 (1986) 297-303
97. Larrosa O., de la Llave Y., Bario S., et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 24 (2001) 282-285
98. U.S. Xyrem® Multicenter Study Group: sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-123.
99. Xyrem® International Study Group: further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 2228 patients. Sleep Med 2005;6:415-21.
100. Tarabar A.F., and Nelson L.S. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 23 (2004) 45-49
101. Mamelak M., Black J., Montplaisir J., and Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 27 7 (2004) 1327-1334 36
102. Thorpy M.J., Snyder M., Aloe F.S., Ledereich P.S., and Starz K.E. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep 15 3 (1992) 212-216
103. Takahashi Y. The action of tricyclics (Alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Guilleminault C., Dement W.C., and Passouant P. (Eds). Narcolepsy (1976), Spectrum, New York 625-642
104. Guilleminault C. Cataplexy. In: Guilleminault C., Dement W.C., and Passouant P. (Eds). Narcolepsy (1976), Spectrum, New York 125-144
105. Mamelak M., Scharf M.B., and Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 9 1 Pt 2 (1986) 285-289
106. Goswami M. The influence of clinical symptoms on quality of life in patients with narcolepsy. Neurology 50 2 Suppl. 1 (1998) S31-S36
107. Beusterien K.M., Rogers A.E., Walsleben J.A., et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22 6 (1999) 757-765
108. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins) [comment]. Cell 98 4 (1999) 409-412
109. Weaver T.E. Sodium oxybate for narcolepsy improves patient quality of life. Sleep 28 (2005) A219
110. Mignot E., and Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 28960 (2005) 754-763
111. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 3 (1999) 365-376
112. Siegel J.M., Nienhuis R., Gulyani S., Ouyang S., Wu M.F., Mignot E., et al. Neuronal degeneration in canine narcolepsy. J Neurosci 19 1 (1999) 248-257
113. Hanson L.R., Martinez P.M., Taheri S., Kamsheh L., Mignot E., and Frey II W.H. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Delivery Technol 4 (2004) 66-71
114. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., and Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 101 13 (2004) 4649-4654
115. Boehmer L.N., Wu M.F., John J., and Siegel J.M. Treatment with immunosuppressive and anti-inflammatory agents delays onsets of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 188 2 (2004) 292-299
116. Schatzberg S.J., Barrett J., Cutter K.I., Ling L., and Mignot E. Case study: effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Internal Med 18 (2004) 586-588
117. Hecht M., Lin L., Kushida C.A., Umetsu D.T., Taheri S., Einen M., et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 26 7 (2003) 809-810
118. Chen W., Black J., Call P., and Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 58 3 (2005) 489-490
119. Lecendreux M., Maret S., Bassetti C., Mouren M.C., and Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 12 4 (2003) 347-348
120. Yves Dauvilliers MD, Bertrand Carlander MD, François Rivier MD, PhD, Jacques Touchon MD, Mehdi Tafti, Ph.D. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56(6):905-8.
121. Zuberi S.M., Mignot E., Ling L., and McArthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res 13 Suppl. 1 (2004) 828
122. Boehmer L.N., Wu M.F., John J., and Siegel J.M. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 188 2 (2004) 292-299
123. Nishino S., Arrigoni J., Shelton J., Kanbayashi T., Dement W.C., and Mignot E. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 17 16 (1997) 6401-6408
124. Riehl J., Honda K., Kwan M., Hong J., Mignot E., and Nishino S. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 23 1 (2000) 34-45
125. Broberger C., and McCormick D.A. Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci 25 7 (2005) 1664-1673
126. Barbier A.J., Berridge C., Dugovic C., Laposky A.D., Wilson S.J., Boggs J., et al. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 143 5 (2004) 649-661
127. Tedford C.E., Phillips J.G., Gregory R., Pawlowski G.P., Fadnis L., Khan M.A., et al. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther 289 2 (1999) 1160-1168
128. Shiba T., Fujiki N., Wisor J., Edgar D., Sakurai T., and Nishino S. Wake promoting effects of thioperamide, a histamin H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep (2004) A241-A242